INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Milène Tetsi Nomigni in
Google Scholar
PubMed
Search for other papers by Sophie Ouzounian in
Google Scholar
PubMed
Search for other papers by Alice Benoit in
Google Scholar
PubMed
Search for other papers by Jacqueline Vadrot in
Google Scholar
PubMed
Search for other papers by Frédérique Tissier in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Sylvie Renouf in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Hervé Lefebvre in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Sophie Christin-Maitre in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Estelle Louiset in
Google Scholar
PubMed
. Polycystic ovary syndrome (PCOS) is the most common cause of hyperandrogenism (1, 2, 3) . According to the Rotterdam criteria, diagnosis of PCOS is determined on the basis of chronic anovulation, polycystic ovaries, clinical and/or biochemical evidence of
Search for other papers by Anastasia K Armeni in
Google Scholar
PubMed
Search for other papers by Konstantinos Assimakopoulos in
Google Scholar
PubMed
Search for other papers by Dimitra Marioli in
Google Scholar
PubMed
Search for other papers by Vassiliki Koika in
Google Scholar
PubMed
Search for other papers by Euthychia Michaelidou in
Google Scholar
PubMed
Search for other papers by Niki Mourtzi in
Google Scholar
PubMed
Search for other papers by Gregoris Iconomou in
Google Scholar
PubMed
Search for other papers by Neoklis A Georgopoulos in
Google Scholar
PubMed
Endocrinology, Department of Obstetrics and Gynaecology of the Medical School, University of Patras. Exclusion criteria were chronic diseases, major psychiatric disorders, use of oral contraceptive pills (OCs), polycystic ovary syndrome (PCOS), thyroid diseases
Search for other papers by Junhui Zhang in
Google Scholar
PubMed
Search for other papers by Hongyan Zhang in
Google Scholar
PubMed
Search for other papers by Bao Guo in
Google Scholar
PubMed
Search for other papers by Jun Yang in
Google Scholar
PubMed
Search for other papers by Renxiang Yu in
Google Scholar
PubMed
Search for other papers by Wenxiu Chen in
Google Scholar
PubMed
Search for other papers by Muxin Zhai in
Google Scholar
PubMed
Search for other papers by Cao Yuhan in
Google Scholar
PubMed
Search for other papers by Yajing Liu in
Google Scholar
PubMed
Search for other papers by Qiang Hong in
Google Scholar
PubMed
Search for other papers by Fenfen Xie in
Google Scholar
PubMed
The elevated level of hepatic oxidative stress (OS) in polycystic ovary syndrome (PCOS) is one of the important causes of liver abnormalities. Therefore, decreasing the level of hepatic OS in PCOS is beneficial to reduce the risk of PCOS-related liver diseases. Melatonin (MT), recognized as a potent antioxidant. Nevertheless, the efficacy of MT in alleviating hepatic OS associated with PCOS is yet to be established, and the precise mechanisms through which MT exerts its antioxidant effects remain to be fully elucidated. The aim of this study was to explore the potential mechanism by which MT reduces hepatic OS in PCOS. First, we detected elevated OS levels in the PCOS samples. Subsequently, with MT pretreatment, we discovered that MT could significantly diminish the levels of OS, liver triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT) and aspartate aminotransferase (AST),while concurrently ameliorating mitochondrial structural damage in PCOS liver. Furthermore, we identified elevated autophagy levels in the liver of PCOS rats and an inhibition of the Keap1-Nrf2 pathway. Through MT pretreatment, the expression of LC3 was significantly decreased, while the Keap1-Nrf2 pathway was activated. Our study showed that MT could affect the Nrf2 pathway dependent on the P62/LC3 autophagy pathway, thereby attenuating hepatic OS in PCOS. These findings offer novel insights and research avenues for the study of PCOS-related liver diseases.
Search for other papers by Jie Yang in
Google Scholar
PubMed
Search for other papers by Min Lin in
Google Scholar
PubMed
Search for other papers by Xiaoyan Tian in
Google Scholar
PubMed
Search for other papers by Chujun Li in
Google Scholar
PubMed
Search for other papers by Haocun Wu in
Google Scholar
PubMed
Search for other papers by Ling Deng in
Google Scholar
PubMed
Search for other papers by Xuelan Li in
Google Scholar
PubMed
Search for other papers by Xin Chen in
Google Scholar
PubMed
Purpose: Our study aimed to assess the relationship between serum adipokines and insulin resistance (IR) in women with polycystic ovary syndrome (PCOS), as well as explore the predictive value of adipokines on IR in PCOS.
Methods: This was a prospective cross-sectional study. 154 women with PCOS were included from July 2021 to September 2022 who underwent gonadal steroid hormone measurement, lipid profile, oral glucose tolerance test and homeostasis model assessment (HOMA)-IR. Adiponectin (APN), leptin and secreted frizzled-related protein (Sfrp5) were measured by immunoturbidimetry and enzyme-linked immunosorbent assay. Women with PCOS were categorised based on the presence of IR.
Results: Women with PCOS with IR (n=99) had significantly lower APN level and APN to leptin ratio (A/L ratio) than those without IR (n=55), whereas serum levels of leptin and Sfrp5 were similar between the two groups. In multivariable linear regression analysis, serum log (APN) and log (A/L ratio) were associated with log(HOMA-IR), the association was statistically significant after adjusting for body mass index (BMI) and free androgen index. The area under the ROC curve (95% CI) for APN and A/L ratio were 0.726 (0.644–0.807; P<0.001) and 0.660(0.569–0.751; P<0.01), with cutoff values of 5.225 mg/L (Youden index ¼ 0.364) and 1.438 (Youden index ¼ 0.265) respectively.
Conclusion: Our study demonstrated that serum APN was negatively related to IR. Serum APN may be useful as a clinical marker for IR in women with PCOS. Our findings warrant further investigations into the function of APN in the pathogenesis of IR in women with PCOS.
Search for other papers by Liza Haqq in
Google Scholar
PubMed
Search for other papers by James McFarlane in
Google Scholar
PubMed
Search for other papers by Gudrun Dieberg in
Google Scholar
PubMed
Search for other papers by Neil Smart in
Google Scholar
PubMed
agency in the public, commercial or not-for-profit sector. References 1 March WA Moore VM Willson KJ Phillips DI Norman RJ Davies MJ . The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Mojca Jensterle in
Google Scholar
PubMed
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Nika Aleksandra Kravos in
Google Scholar
PubMed
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Simona Ferjan in
Google Scholar
PubMed
Search for other papers by Katja Goricar in
Google Scholar
PubMed
Search for other papers by Vita Dolzan in
Google Scholar
PubMed
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Andrej Janez in
Google Scholar
PubMed
polycystic ovary syndrome . Diabetes Care 2019 560 – 567 . ( https://doi.org/10.2337/dc18-1738 ) 3 Velazquez EM Mendoza S Hamer T Sosa F Glueck CJ . Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance
Search for other papers by Gunjan Garg in
Google Scholar
PubMed
Search for other papers by Garima Kachhawa in
Google Scholar
PubMed
Search for other papers by Rekha Ramot in
Google Scholar
PubMed
Search for other papers by Rajesh Khadgawat in
Google Scholar
PubMed
Search for other papers by Nikhil Tandon in
Google Scholar
PubMed
Search for other papers by V Sreenivas in
Google Scholar
PubMed
Search for other papers by Alka Kriplani in
Google Scholar
PubMed
Search for other papers by N Gupta in
Google Scholar
PubMed
sensitivity in apparently healthy, middle-aged, centrally obese men . Diabetic Medicine 2009 26 19 – 27 . ( doi:10.1111/j.1464-5491.2008.02636.x ). 9 Diamanti-Kandarakis E Dunaif A . Insulin resistance and the polycystic ovary syndrome revisited
Search for other papers by Thomas Reinehr in
Google Scholar
PubMed
Search for other papers by Alexandra Kulle in
Google Scholar
PubMed
Search for other papers by Juliane Rothermel in
Google Scholar
PubMed
Search for other papers by Caroline Knop-Schmenn in
Google Scholar
PubMed
Search for other papers by Nina Lass in
Google Scholar
PubMed
Search for other papers by Christina Bosse in
Google Scholar
PubMed
Search for other papers by Paul-Martin Holterhus in
Google Scholar
PubMed
. References 1 Franks S. Polycystic ovary syndrome in adolescents . International Journal of Obesity 2008 32 1035 – 1041 . ( doi:10.1038/ijo.2008.61 ) 2 Ehrmann DA. Polycystic ovary syndrome . New England Journal of Medicine 2005 352
Search for other papers by Yael Sofer in
Google Scholar
PubMed
Search for other papers by Nava Nevo in
Google Scholar
PubMed
Search for other papers by Michal Vechoropoulos in
Google Scholar
PubMed
Search for other papers by Gabi Shefer in
Google Scholar
PubMed
Search for other papers by Etty Osher in
Google Scholar
PubMed
Search for other papers by Nathan Landis in
Google Scholar
PubMed
Search for other papers by Karen Tordjman in
Google Scholar
PubMed
Search for other papers by Geoffrey L Hammond in
Google Scholar
PubMed
Search for other papers by Naftali Stern in
Google Scholar
PubMed
levels and HbA1c ( 11 , 13 ). Hypoandrogenism in men and hyperandrogenism in women (e.g., the polycystic ovary syndrome) have been linked to insulin resistance and the metabolic syndrome ( 13 , 14 ). In one report, SHBG levels predicted the development
Search for other papers by Line K Johnson in
Google Scholar
PubMed
Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway
Search for other papers by Kirsten B Holven in
Google Scholar
PubMed
Search for other papers by Njord Nordstrand in
Google Scholar
PubMed
Search for other papers by Jan R Mellembakken in
Google Scholar
PubMed
Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway
Search for other papers by Tom Tanbo in
Google Scholar
PubMed
Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway
Search for other papers by Jøran Hjelmesæth in
Google Scholar
PubMed
assessment; and Matthew McGee for proofreading the manuscript. References 1 Carmina E Bucchieri S Esposito A Del Puente A Mansueto P Orio F Di Fede G Rini G . Abdominal fat quantity and distribution in women with polycystic ovary syndrome and